Protease inhibitors and cardiovascular disease: analysis of the Los Angeles County adult spectrum of disease cohort

References

• Behrens , G. , Dejam , A. , Schmidt , H. , Balks , H. J. , Brabant , G. , Korner , T. , Stoll , M. and Schmidt , R. E. 1999 . Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors . AIDS , 13 : F63 – F70 .
   PubMed Web of Science ®Google Scholar
• Berthold , H. K. , Parhofer , K. G. , Ritter , M. M. , Addo , M. , Wasmuth , J. C. , Schliefer , K. , Spengler , U. and Rockstroh , J. K. 1999 . Influence of protease inhibitor therapy on lipoprotein metabolism . Journal of Internal Medicine , 246 : 567 – 75 .
   PubMed Web of Science ®Google Scholar
• Bozzette , S. A. , Ake , C. F. , Tam , H. K , Chang , S. W. and Louis , T. A. 2003 . Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection . New England Journal of Medicine , 348 : 702 – 10 .
   PubMed Web of Science ®Google Scholar
• Carr , A. , Samaras , K. , Burton , S. , Law , M. , Freund , J. , Chisholm , D. J. and Cooper , D. A. 1998a . A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors . AIDS , 12 : F51 – F58 .
   PubMed Web of Science ®Google Scholar
• Carr , A. , Samaras , K. , Chisholm , D. J. and Cooper , D.A. 1998b . Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance . Lancet , 351 : 1881 – 83 .
   PubMed Web of Science ®Google Scholar
• Danner , S. A. , Carr , A. , Leonard , J. M. , Lehman , L. M. , Gudiol , F. , Gonzales , J. , Raventos , A. , Rubio , R. , Bouza , E. and Pintado , V. 1995 . A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group . New England Journal of Medicine , 333 : 1528 – 33 .
   PubMed Web of Science ®Google Scholar
• Detels , R. , Muñoz , A. , McFarlane , G. , Kingsley , L. A. , Margolick , J. , Giorgi , J. , Schrager , L. K. and Phair , J.P. 1998 . Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration . JAMA , 280 ( 17 ) : 1497 – 503 .
   PubMed Web of Science ®Google Scholar
• Dube , M. P. , Stein , J. H. , Aberg , J. A. , Fichtenbaum , C. J. , Gerber , J. G. , Tashima , K. T. , Henry , W. K. , Currier , J. S. , Sprecher , D. and Glesby , M. J. 2003 . Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group . Clinical Infectious Diseases , 37 : 613 – 27 .
   PubMed Web of Science ®Google Scholar
• Farizo , K. M. , Buehler , J.W. , Chamberland , M. E. , Whyte , B. M. , Froelicher , E. S. , Hopkins , S. G. , Reed , C. M. , Mokotoff E. D. , Cohn , D. L. , & Troxler , S. ( 1992 ). Spectrum of disease in persons with human immunodeficiency virus infection in the United States . Journal of the American Medical Association , 267 , pp. 1798 – 805 .
   PubMed Web of Science ®Google Scholar
• Friis-Moller , N. , Weber , R. , Reiss , P. , Thiebaut , R. , Kirk , O. , d'Arminio Monforte , A. , Pradier , C. , Morfeldt , L. , Mateu , S. , Law , M. , El-Sadr , W. , De Wit , S. , Sabin , C. A. , Phillips , A. N. , Lundgren , J. D. For the Dad Study Group ( 2003 ). Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study . AIDS , 17 , pp. 1179 – 93 .
   PubMed Web of Science ®Google Scholar
• Friis-Moller , N. , Sabin , C. A. , Weber , R. , d'Arminio Monforte , A. , El-Sadr , W. M. , Reiss , P. , Thiebaut , R. , Morfeldt , L. , De Wit , S. , Pradier , C. , Calvo , G. , Law , M. G. , Kirk , O. , Phillips , A. N. , Lundgren , J. D. ; Data collection on adverse events of anti-HIV drugs (Dad) Study Group ( 2003 ). Combination antiretroviral therapy and the risk of myocardial infarction . New England Journal of Medicine , 349 , 1993 – 2003 .
   PubMed Web of Science ®Google Scholar
• HIV Epidemiology Program, Los Angeles County Department of Health Services ( 2001 ). Adult and Adolescent Spectrum of HIV Disease (ASD) Semi-Annual Summary Report .
   Google Scholar
• Iloeje , U. H. , Yuan , Y. , L'italien , G. , Mauskopf , J. , Holmberg , S. D. , Moorman , A. C. , Wood , K. C. and Moore , R. D. 2005 . Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients . HIV Medicine , 6 : 37 – 44 .
   PubMed Web of Science ®Google Scholar
• Klein , D. , Hurley , L. B. , Quesenberry , C. P. J. and Sidney , S. 2002 . Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? . Journal of Acquired Immune Deficiency Syndrome , 30 : 471 – 77 .
   PubMed Web of Science ®Google Scholar
• Ledergerber , B. , Egger , M. , Opravil , M. , Telenti , A. , Hirschel , B. , Battegay , M. , Vernazza , P. , Sudre , P. , Flepp , M. , Furrer , H. , Francioli , P. and Weber , R. 1999 . Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study . Lancet , 353 : 863 – 68 .
   PubMed Web of Science ®Google Scholar
• Lucas , G. M. , Chaisson , R. E. , & Moore , R. D. ( 2001 ). Comparison of initial combination therapy with a single protease inhibitor, ritonavir and sequinavir, or efavirenz [abstract #686] . Infectious Diseases Society of America 39th meeting .
   Google Scholar
• Martinez , E. , Conget , I. , Lozano , L. , Casamitjana , R. and Gatell , J.M. 1999 . Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine . AIDS , 13 : 805 – 810 .
   PubMed Web of Science ®Google Scholar
• Mary-Krause , M. , Cotte , L. , Simon , A. , Partisani , M. and Costagliola , D. 2003 . Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men . AIDS , 17 : 2479 – 86 .
   PubMed Web of Science ®Google Scholar
• Palella , F J. J. , Delaney , K. M. , Moorman , A. C. , Loveless , M. O. , Fuhrer , J. , Satten , G. A. , Aschman , D. J. and Holmberg , S. D. 1998 . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators . New England Journal of Medicine , 338 : 853 – 60 .
   PubMed Web of Science ®Google Scholar
• Parenti , D. , Ruane , P. , Margolis , D. , Shepp , D. H. , Babinchak , T. J. , Van Kempen , A. S. , Kauf , T. L. , Danehower , S. A. , Yau , L. , Hessenthaler , S. M. , Goodwin , D. , Hernandez , J. E. ; COL30336 Study Team (2001). The compact quad, combavir/ abacavir/efavirenz (COM/ABC/EFV) – preliminary 48-wk results (COL30336) [abstract #697] . Infectious Diseases Society of America 39th meeting .
   Google Scholar
• Periard , D. , Telenti , A. , Sudre , P. , Cheseaux , J. J. , Halfon , P. , Reymond , M. J. , Marcovina , S. M. , Glauser , M. P. , Nicod , P. , Darioli , R. and Mooser , V. 1999 . Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study . Circulation , 100 : 700 – 05 .
   PubMed Web of Science ®Google Scholar
• Pulvirenti , J. , Goodwin , D. , & Slater , L. , et al. ( 2001 ). Simplification of protease inhibitor (PI)-containing HAART regimens with abacavir (ABC) maintains viral suppression and favorable adherence in HIV-1 infected adults (COLA 30305) [abstract #689] . Infectious Diseases Society of America 39th meeting .
   Google Scholar
• Rubin , D. B. 1987 . Multiple imputation for nonresponse in surveys , New York , NY : John Wiley & Sons, Inc .
   Google Scholar
• Sgadari , C. , Monini , P. , Barillari , G. and Ensoli , B. 2003 . Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth . Lancet , 4 : 537 – 47 .
   PubMed Web of Science ®Google Scholar